157 related articles for article (PubMed ID: 30937392)
1. Bevacizumab as a steroid-sparing agent during immunotherapy for melanoma brain metastases: A case series.
Banks PD; Lasocki A; Lau PKH; Sandhu S; McArthur G; Shackleton M
Health Sci Rep; 2019 Mar; 2(3):e115. PubMed ID: 30937392
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab as an effective treatment for radiation necrosis after radiotherapy for melanoma brain metastases.
Glitza IC; Guha-Thakurta N; D'Souza NM; Amaria RN; McGovern SL; Rao G; Li J
Melanoma Res; 2017 Dec; 27(6):580-584. PubMed ID: 28817446
[TBL] [Abstract][Full Text] [Related]
3. Intracranial Control With Combination BRAF and MEK Inhibitor Therapy in Patients With Metastatic Melanoma.
Hui C; Wu YF; Liu K; Sandhu N; Blomain E; Binkley MS; Gephart MH; Chang SD; Li GH; Reddy SA; Soltys SG; Pollom E
Cureus; 2022 Nov; 14(11):e31838. PubMed ID: 36579260
[TBL] [Abstract][Full Text] [Related]
4. A new strategy of CyberKnife treatment system based radiosurgery followed by early use of adjuvant bevacizumab treatment for brain metastasis with extensive cerebral edema.
Wang Y; Wang E; Pan L; Dai J; Zhang N; Wang X; Liu X; Mei G; Sheng X
J Neurooncol; 2014 Sep; 119(2):369-76. PubMed ID: 24879376
[TBL] [Abstract][Full Text] [Related]
5. Stereotactic radiosurgery with whole brain radiotherapy combined with bevacizumab in the treatment of brain metastases from NSCLC.
Li L; Feng M; Xu P; Wu YL; Yin J; Huang Y; Tan MY; Jinyi L
Int J Neurosci; 2023 Mar; 133(3):334-341. PubMed ID: 33843421
[TBL] [Abstract][Full Text] [Related]
6. Local control after stereotactic radiosurgery for brain metastases in patients with melanoma with and without BRAF mutation and treatment.
Ly D; Bagshaw HP; Anker CJ; Tward JD; Grossmann KF; Jensen RL; Shrieve DC
J Neurosurg; 2015 Aug; 123(2):395-401. PubMed ID: 25768829
[TBL] [Abstract][Full Text] [Related]
7. Continuous Low-Dose Apatinib Combined With WBRT Significantly Reduces Peritumoral Edema and Enhances the Efficacy of Symptomatic Multiple Brain Metastases in NSCLC.
Ren Y; Wang SB; Zhou L; Liu SQ; Du LY; Li T; Jiang MQ; Lei KJ; Tan BX; Jia YM
Technol Cancer Res Treat; 2021; 20():15330338211011968. PubMed ID: 33955301
[TBL] [Abstract][Full Text] [Related]
8. Targeted intraarterial anti-VEGF therapy for medically refractory radiation necrosis in the brain.
Dashti SR; Spalding A; Kadner RJ; Yao T; Kumar A; Sun DA; LaRocca R
J Neurosurg Pediatr; 2015 Jan; 15(1):20-5. PubMed ID: 25360851
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of bevacizumab combined with chemotherapy in symptomatic brain metastases from lung adenocarcinoma: a retrospective analysis.
Zhan Q; Miao F; Huang R; Zhou X; Ge M; Liang X
J Thorac Dis; 2019 Nov; 11(11):4725-4734. PubMed ID: 31903262
[TBL] [Abstract][Full Text] [Related]
10. The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study.
Martins F; Schiappacasse L; Levivier M; Tuleasca C; Cuendet MA; Aedo-Lopez V; Gautron Moura B; Homicsko K; Bettini A; Berthod G; Gérard CL; Wicky A; Bourhis J; Michielin O
J Neurooncol; 2020 Jan; 146(1):181-193. PubMed ID: 31836957
[TBL] [Abstract][Full Text] [Related]
11. BRAF V600E mutation and BRAF kinase inhibitors in conjunction with stereotactic radiosurgery for intracranial melanoma metastases.
Xu Z; Lee CC; Ramesh A; Mueller AC; Schlesinger D; Cohen-Inbar O; Shih HH; Sheehan JP
J Neurosurg; 2017 Mar; 126(3):726-734. PubMed ID: 27203149
[TBL] [Abstract][Full Text] [Related]
12. Melanoma brain metastasis presentation, treatment, and outcomes in the age of targeted and immunotherapies.
Bander ED; Yuan M; Carnevale JA; Reiner AS; Panageas KS; Postow MA; Tabar V; Moss NS
Cancer; 2021 Jun; 127(12):2062-2073. PubMed ID: 33651913
[TBL] [Abstract][Full Text] [Related]
13. The changing paradigm of management in melanoma brain metastases.
Ladwa R; Atkinson V
Asia Pac J Clin Oncol; 2018 Dec; 14(6):453-458. PubMed ID: 29932306
[TBL] [Abstract][Full Text] [Related]
14. The effect of timing of stereotactic radiosurgery treatment of melanoma brain metastases treated with ipilimumab.
Cohen-Inbar O; Shih HH; Xu Z; Schlesinger D; Sheehan JP
J Neurosurg; 2017 Nov; 127(5):1007-1014. PubMed ID: 28059663
[TBL] [Abstract][Full Text] [Related]
15. The impact of timing of immunotherapy with cranial irradiation in melanoma patients with brain metastases: intracranial progression, survival and toxicity.
Rahman R; Cortes A; Niemierko A; Oh KS; Flaherty KT; Lawrence DP; Sullivan RJ; Shih HA
J Neurooncol; 2018 Jun; 138(2):299-306. PubMed ID: 29453679
[TBL] [Abstract][Full Text] [Related]
16. Potential role for LINAC-based stereotactic radiosurgery for the treatment of 5 or more radioresistant melanoma brain metastases.
Frakes JM; Figura NB; Ahmed KA; Juan TH; Patel N; Latifi K; Sarangkasiri S; Strom TJ; Chinnaiyan P; Rao NG; Etame AB
J Neurosurg; 2015 Nov; 123(5):1261-7. PubMed ID: 26140482
[TBL] [Abstract][Full Text] [Related]
17. Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment.
Anderson ES; Postow MA; Wolchok JD; Young RJ; Ballangrud Å; Chan TA; Yamada Y; Beal K
J Immunother Cancer; 2017 Oct; 5(1):76. PubMed ID: 29037215
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab as a treatment for radiation necrosis following stereotactic radiosurgery for brain metastases: clinical and radiation dosimetric impacts.
Li J; He J; Cai L; Lai M; Hu Q; Ren C; Wen L; Wang J; Zhou J; Zhou Z; Li S; Ye M; Shan C; Chen L; Zhou C
Ann Palliat Med; 2021 Feb; 10(2):2018-2026. PubMed ID: 33549015
[TBL] [Abstract][Full Text] [Related]
19. Mutational Status and Clinical Outcomes Following Systemic Therapy with or without Focal Radiation for Resected Melanoma Brain Metastases.
Vasudevan HN; Susko MS; Ma L; Nakamura JL; Raleigh DR; Boreta L; Fogh S; Theodosopoulos PV; McDermott MW; Tsai KK; Sneed PK; Braunstein SE
World Neurosurg; 2023 Feb; 170():e514-e519. PubMed ID: 36400359
[TBL] [Abstract][Full Text] [Related]
20. First line immunotherapy extends brain metastasis free survival, improves overall survival, and reduces the incidence of brain metastasis in patients with advanced melanoma.
Wang X; Haaland B; Hu-Lieskovan S; Colman H; Holmen SL
Cancer Rep (Hoboken); 2021 Dec; 4(6):e1419. PubMed ID: 34137219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
